Aldeyra CEO to Participate in 2026 Jefferies Healthcare Conference
Aldeyra Therapeutics announced CEO Dr. Todd Brady will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, in New York. The live webcast will be available on the company's website and archived for 90 days. Aldeyra is a biotechnology company focused on therapies for immune-mediated diseases.
Aldeyra Therapeutics, Inc. announced that President and Chief Executive Officer Todd C. Brady, M.D., Ph.D., will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York, New York. The conversation is scheduled to begin at 8:45 a.m. ET on Thursday, June 4, 2026.
A live webcast of the event will be available on the Investors & Media section of the Aldeyra website. Following the fireside chat, the webcast will be archived for 90 days.
Aldeyra Therapeutics is a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases. The company develops pharmaceuticals that modulate protein systems to optimize multiple pathways while minimizing toxicity. Its product candidates include RASP modulators ADX‑248 and ADX-246, as well as late-stage candidates reproxalap for dry eye disease and allergic conjunctivitis, and ADX-2191 for primary vitreoretinal lymphoma and retinitis pigmentosa.